PBPK-based predictors for long-acting injectable suspensions
Official title: Development of PBPK Model-Based Mechanistic IVIVCs for Long-Acting Injectable Suspensions
Funded at University of Connecticut Storrs · NIH-11401621 · Data updated 2026-11-12
Researchers will build computer models to predict how long-acting injectable suspensions release medicine in the body, helping ensure effective and safe dosing for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Storrs NIH-funded |
| Lab location | 1 site (Storrs-Mansfield, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $362,790 |
| NIH project number | 5U01FD008304-03 |
| Project ID | NIH-11401621 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients who could benefit from long-acting injectable therapies and participate in future development or testing of LAI products and related models.
✕Less likely to help
Patients not using LAI therapies or outside the scope of this modeling effort may not directly benefit from this project.
What this research studies
This project uses physiologically based pharmacokinetic models to connect how LAI suspension formulations release drug at the injection site with how the medicine behaves in the body over time. The team will study how formulation attributes influence depot formation and local physiology to improve in silico predictions of drug release and bioavailability. By linking formulation factors to in vivo outcomes, they aim to support robust IVIVCs and facilitate generic LAI development. The work combines mechanistic modeling with experimental data to better anticipate patient responses and dosing needs. Results could help patients access reliable LAI therapies sooner with clearer guidance for regulators and manufacturers.
Why it matters
Potential benefit: If successful, this work could make LAI medicines more predictable and affordable, improving access and treatment consistency for patients needing long-acting therapies.
How similar studies have gone: Previous modeling efforts have shown promise in predicting drug release and guiding formulation decisions, but robust IVIVCs for LAI suspensions remain an area of active development.
Where this research is happening
-
University of Connecticut Storrs
Storrs-Mansfield, United States Active
Researchers
- Principal investigator: Burgess, Diane Jane — University of Connecticut Storrs
- Study coordinator: Burgess, Diane Jane
Related research
Other NIH-funded projects on the same topics.
-
New sequencing machine to boost veterinary genomics at CVMDL
A new high-throughput DNA/RNA sequencer will be acquired and put into use at the Connecticut Veterinary Medical Diagnostic Laboratory to improve how we study and diagnose animal diseases.
-
How IL-10 changes mast cells in allergic reactions
This work looks at how the immune signal IL-10 changes mast cells and their responses in people with food allergies.
-
Optimizing a just-in-time intervention to help MSM access chemsex harm-reduction services
A smartphone app-driven approach tests personalized, timely support to help men who have sex with men access chemsex harm-reduction services and reduce HIV risk.
-
Understanding how vagus nerve stimulation helps stroke recovery to guide better treatments
This NIH grant uses computer models to figure out how brief, task-timed vagus nerve stimulation affects the brain after stroke and helps movement recovery.
-
Targeting c-Myc DNA with next-generation nucleic acid tools in aggressive B-cell lymphomas
This grant tests a new way to slow or stop aggressive B-cell lymphomas by directly targeting the c-Myc gene in patients and model systems using advanced nucleic acid analogs.
-
Soft, bendable 3D electronics and microfluidic micro-labs for drug screening in engineered tissues
A team at the University of Connecticut is building a soft, 3D electronic and microfluidic platform to grow human organoids and test drugs safely and accurately.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.